Survival analysis is the widely used statistical tool for new intervention comparison in presence of hazards of follow up studies. However, it is difficult to obtain suitable survival rate in presence of high level of hazard within few days of surgery. The group of patients can be directly stratified into cured and non-cured strata. The mixture models are natural choice for estimation of cure and non-cure rate estimation. The estimation of cure rate is an important parameter of success of any new intervention. The cure rate model is illustrated to compare the surgery of liver cirrhosis patients with consenting for participation HFLPC (Human Fatal Liver Progenitor Cells) Infusion vs. consenting for participation alone group in South Indian popula-tion. The surgery is best available technique for liver cirrhosis treatment. The success of the surgery is observed through follow up study. In this study, MELD (Model for End-Stage Liver Disease) score is considered as response of interest for cured and non-cured group. The primary efficacy of surgery is considered as covariates of interest. Distributional assumptions of the cure rate are solved with Markov Chain Monte Carlo (MCMC) techniques. It is found that cured model with parametric approach allows more consistent estimates in comparison to standard procedures. The risk of death due to liver transplantation in liver cirrhosis patients including time dependent effect terms has also been explored. The approach assists to model with different age and sex in both the treatment groups.
The surrogate markers(SM) are the important factor for angiogenesis in cancer patients.In Metronomic Chemotherapy (MC) , physicians administer subtoxic doses of chemotherapy (without break) for long periods, to the target tumor angiogenesis. We propose a semiparametric approach, predictive risk modeling and time to control the level of surrogate marker to detect the perfect dose level of MC. It is based on the controlled level of surrogate marker, and the aim is to detect an Optimum Biological Dose (OBD) finding rather than a traditional Maximum Tolerated Dose (MTD) approach. The methods are illustrated with MC trial dataset to determine the best OBD and we investigate the performance of the model through simulation studies.